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Abstract 
  Bone is constantly being molded and shaped by the action of osteoclasts and 
osteoblasts. A proper equilibrium between both cell types metabolic activities is 
required to ensure an adequate skeletal tissue structure, and it involves resorption of old 
bone and formation of new bone tissue. It is reported that treatment with antiepileptic 
drugs (AEDs) can elicit alterations in skeletal structure, in particular in bone mineral 
density. Nevertheless, the knowledge regarding the effects of AEDs on bone cells are 
still scarce. In this context, the aim of this study was to investigate the effects of five 
different AEDs on human osteoclastic, osteoblastic and co-cultured cells. 
Osteoclastic cell cultures were established from precursor cells isolated from 
human peripheral blood and were characterized for tartrate-resistant acid phosphatase 
(TRAP) activity, number of TRAP+ multinucleated cells, presence of cells with actin 
rings and expressing vitronectin and calcitonin receptors and apoptosis rate. Also, the 
involvement of several signaling pathways on the cellular response was addressed. 
Osteoblastic cell cultures were obtained from femur heads of patients (25-45 
years old) undergoing orthopaedic surgery procedures and were then studied for cellular 
proliferation/viability, ALP activity, histochemical staining of ALP and apoptosis rate. 
Also the expression of osteoblast-related genes and the involvement of some 
osteoblastogenesis-related signalling pathways on cellular response were addressed.  
For co-cultured cells, osteoblastic cells were firstly seeded and cultured.  After 
that, PBMC were added to the osteoblastic cells and co-cultures were evaluated using 
the same osteoclast and osteoblast parameters mentioned above for the corresponding 
isolated cell. 
Cell-cultures were maintained in the absence (control) or in the presence of 
different AEDs (carbamazepine, gabapentin, lamotrigine, topiramate and valproic acid). 
All the tested drugs were able to affect osteoclastic and osteoblastic cells 
development, although with different profiles on their osteoclastogenic and 
osteoblastogenic modulation properties. Globally, the tendency was to inhibit the 
process. Furthermore, the signaling pathways involved in the process also seemed to be 
differently affected by the AEDs, suggesting that the different drugs may affect 
osteoclastogenesis and/or osteoblastogenesis through different mechanisms. 
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In conclusion, the present study showed that the different AEDs had the ability 
to directly and indirectly modulate bone cells differentiation, shedding new light 
towards a better understanding of how these drugs can affect bone tissue. 
 
Keywords: Bone remodeling, osteoclastic cells, osteoblastic cells, osteoclastogenesis, 
osteoblastogenesis, antiepileptic drugs, epilepsy.  
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Resumo 
 O tecido ósseo sofre remodelação constante por ação dos osteoclastos e 
osteoblastos. Um equilíbrio adequado entre as atividades metabólicas de ambas as 
células torna-se essencial para garantir uma estrutura apropriada do tecido esquelético, e 
envolve a reabsorção de osso velho e consequente formação de novo tecido ósseo. 
Alterações na estrutura esquelética, em particular na densidade mineral óssea, por parte 
de fármacos antiepilépticos, foram já documentadas. No entanto, o conhecimento acerca 
dos efeitos destes fármacos nas células ósseas é ainda escasso. Posto isto, o principal 
objetivo deste estudo foi investigar o efeito de cinco antiepilépticos diferentes em 
células ósseas humanas (osteoclastos, osteoblastos e culturas de ambas as células). 
 As culturas celulares de osteoclastos foram instituídas a partir de células 
percursoras isoladas de sangue periférico humano e caracterizadas para a atividade da 
TRAP (fosfatase ácida resistente ao tartarato), número de células multinucleadas TRAP 
positivas, presença de células com anéis de actina e que expressam recetores de 
vitronectina e calcitonina e taxa de apoptose. Para além disto, também o envolvimento 
de vias de sinalização na resposta celular foi testado.  
As culturas celulares de osteoblastos foram obtidas a partir de cabeças de fémur 
de pacientes (25-45 anos) submetidos a cirurgia ortopédica e foram também 
caracterizadas para proliferação/viabilidade celular, atividade da ALP (fosfatase 
alcalina), e taxa de apoptose. Para além disto, também a expressão de genes 
relacionados com osteoblastos e o envolvimento de vias de sinalização na resposta 
celular foram estudadas.  
Relativamente às co-culturas, em primeiro lugar as células osteoblásticas foram 
semeadas e cultivadas. De seguida, as células mononucleadas do sangue periférico 
(PBMC) foram adicionadas às células osteoblásticas e as co-culturas foram avaliadas 
para os mesmos parâmetros mencionados para as células osteoclásticas e osteoblásticas.  
As culturas celulares estudadas foram mantidas na ausência (controlo) ou na 
presença de cinco antiepiléticos diferentes (carbamazepina, gabapentina, lamotrigina, 
topiramato e ácido valpróico).  
Todos os fármacos testados foram capazes de afetar o desenvolvimento das 
células osteoclásticas e osteoblásticas, no entanto, mostraram modular de forma 
diferente estes processos.  
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De um modo geral, a tendência foi para inibir o processo de desenvolvimento de 
ambas as células. Adicionalmente, as vias de sinalização envolvidas também parecem 
ter sido afetadas pelos diferentes fármacos, sugerindo que estes podem afetar a 
osteoclastogénese e a osteoblastogénese por diferentes mecanismos.  
Em jeito de conclusão, o presente estudo mostrou que os diferentes fármacos 
antiepilépticos possuem a capacidade de modular direta e indiretamente a diferenciação 
das células ósseas, fornecendo novas luzes para uma melhor compreensão de como 
estes fármacos podem afetar o tecido ósseo.  
 
Palavras-chave: Remodelação óssea, osteoclastos, osteoblastos, osteoclastogénese, 
osteoblastogénese, antiepilépticos, epilepsia.  
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1.1 Bone 
Contrary to the commonly held misconception, bone is a hard connective tissue and 
a dynamic organ that undergoes significant turnover as compared to other organs in the 
body (1). This organ has well recognized functions including structural support for the 
muscles, protection of vital organs and hematopoietic marrow, and storage and release 
of vital ions, such as calcium and of growth factors stored in the matrix (2). In addition, 
Guntur A., et al (3), also described the bone as an endocrine organ able to secrete its 
own factors to modulate metabolic functions. Bone is a highly vascularized tissue with a 
unique capacity to heal and remodel without scaring (4, 5). It is renewed continuously 
in the adult skeleton in response to a variety of stimuli by the process of bone 
remodeling (2). This remodeling is made possible by a group of specialized cells - 
osteoclasts, osteoblasts and osteocytes. A disruption or imbalance in this process can 
lead to either an increase or decrease in bone mineral density that may be detrimental to 
skeletal strength (3). So that bone strength is maintained, the process of bone turnover 
must be carefully regulated (1). 
1.2 Bone: anatomy  
The human body contains more than 200 bones, which can be classified as either 
long, short, flat or irregular (6, 7). Long bones are longer rather than wider. Most bones 
of the upper and lower limbs are long bones. Short bones are about as broad as they are 
long. They are almost cube-shaped or round. The wrist and ankle bones (carpals) and 
(tarsals) are short bones (4). Flat bones have a relatively thin, flattened shape and are 
frequently curved. Skull bones, the breastbone (sternum), ribs and shoulder blades 
(scapulae) are examples of flat bones. Irregular bones don’t fit easily into the other three 
categories (1, 6).  
The normal structure of bones and their shape depend on two extraosseous 
influences: their interaction with the muscles and the hormonal regulation of calcium 
and phosphate metabolism. The proper balance between bone formation and bone 
resorption is crucial to the normal structure of bones (7).   
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1.2.1 Structure of the long bone 
The growing long bone has three major components: the diaphysis, epiphysis, 
and epiphyseal plate. The diaphysis, also called shaft, is composed mostly of compact 
bone, which is fundamentally bone matrix and cells arranged into elementary units 
called osteons (6, 7). Compact bone is practically solid, being only 10% porous (4, 5). 
The epiphysis, or bone end, is composed primarily of spongy (or cancellous) bone, 
which is mostly cavities surrounded by bone matrix (6). Spongy bone has a higher 
porosity (50-90%) (4).  The surface of the epiphysis is a layer of compact bone. The 
epiphyseal or growth plate is covered by hyaline cartilage, which contains large 
amounts of both collagen fibers and proteoglycans, located between the epiphysis and 
diaphysis (6). The growth plate and the adjacent terminal diaphysis are the most 
metabolically active segment of long bones (7). Together with the small spaces within 
spongy bone and compact bone, the diaphysis of a long bone can have a large space 
called the medullary cavity. This cavity and the cavities of spongy bone are filled with 
marrow (6).  
1.2.2 Structure of  the short, flat and irregular bone 
Short and irregular bones have a similar composition to the epiphysis of long 
bones.  They have compact bone surfaces that surround a spongy bone center with small 
spaces that usually are filled with marrow. Also, they have no diaphysis (because they 
are not elongated). Flat bones usually have no diaphysis or epiphysis and they contain 
an internal framework of spongy bone between two layers of compact bone (6).  
1.3 Bone: major functions  
Bone is involved in a serious of processes which are found to be essential in the 
human body (4). It provides important functions (Table 1), such as support, protection, 
movement, storage and the production of blood cells (6). 
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Table 1 - Functions of the skeletal system 
Function Description 
Support 
Bones, which are rigid and strong, are the 
major supporting tissue of the body. 
Cartilage provides a firm yet flexible 
support and ligaments (strong bands of 
fibrous connective tissue) attach to bone 
and hold them together. 
Protection 
Bone is hard and gives protection to the 
organ it surrounds. 
Movement 
The contraction of the skeletal muscles 
causes the bones to move, producing body 
movements. These muscles are attached to 
the bone by tendons (strong bands of 
connective tissue). 
Storage 
Some minerals in the blood are taken by 
the bone and stored. If blood levels of 
these minerals become lower, the minerals 
are released from bone into the blood. The 
main minerals stored are calcium and 
phosphorus. Adipose tissue is also stored 
in bone cavities. 
Blood cell production 
Many bones contain cavities filled with 
bone marrow that gives rise to blood cells 
and platelets. 
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1.4 Bone: histology and physiology    
Bones are composed by cells and extracellular matrix (osteoid). The inside surface 
of the compact bone and the spongy are covered with bone-forming cells (osteoblasts) 
and bone-resorbing cells (osteoclasts) (7). The composition of the bone matrix 
characterizes the bone. The bone cells produce the bone matrix, become enclosed within 
it, and break it down so that new matrix can replace the old matrix (6). 
1.4.1 Bone matrix: organic and inorganic phase  
Most of the outstanding properties of bone are related to its matrix composition 
(4). Bone is constituted by both mineral (inorganic) and organic phases (8). The organic 
material, which by weight is approximately 35% of the whole mature bone matrix, 
primarily is consisted of not only collagens and proteoglycans but also glycoproteins, 
sialoproteins and bone “gla” proteins (4). To better understand this, the components of 
bone organic phase are summarized in Table 2. The inorganic material (the remaining 
65%) primarily consists of calcium phosphate crystals in the form of hydroxyapatite 
(Ca10(PO4)6(OH)2). Both phases are responsible for the major functional characteristics 
of bone. Collagen lends flexible strength to the matrix, however the mineral 
components give the matrix compression strength (weight bearing). If the entire mineral 
is removed from a long bone, collagen becomes the main constituent, and the bone 
becomes overly flexible. On the other hand, if the collagen is removed from the bone, 
the mineral component becomes the primary constituent, and the bone becomes brittle 
(6).  
1.4.2 Bone cells 
Although bone tissue is populated by a variety of different cells, the synthesis, 
maintenance and resorption of this outstanding tissue results mainly from the interaction 
of three cell types: osteoclasts, osteoblasts and osteocytes (4, 5). All of them have 
defined tasks and are thus essential for the maintenance of a healthy bone tissue (4).  
Osteoblasts and osteoclasts have closely related activities although they originate from 
different cellular lineages and possess opposite functions within the bone remodeling 
cascade (9). The osteoblast produces the matrix which becomes mineralized in a well 
regulated fashion. This mineralized matrix can be removed by the activity of the 
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osteoclast when activated (8). Tissue yielded by osteoblastic formation is maintained by 
the osteocytes (10).  Bone cell types, morphological characteristics and respective 
functions are summarized in Table 3.  
Table 2 - Components of the bone organic phase. Adapted from Macromol. Biosci (2004), 4: 743-
765.  
Bone extracellular matrix components Functions and properties 
Collagen type I Provides framework for skeletal structure. 
Byglican and Decorin 
Proteoglycans. Affect collagen fiber 
growth and diameter. 
Osteonectin 
Glycoprotein. Binds Ca
2+ 
and collagen. 
Nucleates hydroxyapatite. 
Thrombospondin 
Glycoprotein. Binds calcium, 
hydroxyapatite, osteonectin and other cell 
surface proteins. 
Fibronectin Osteoblast attachment to surface. 
Osteopontin 
Sialoprotein. Involved in bone 
remodeling. 
Bone Sialoprotein Sialoprotein. Constituent of cement line. 
Osteocalcin 
Skeletal gla protein. Involved in bone 
remodeling. 
 
1.4.2.1 Osteoclasts 
The osteoclast is a tissue-specific macrophage polykaryon created by the 
differentiation of monocyte/macrophage precursors cells at or near the bone surface 
(11). Osteoclasts are large cells with several nuclei and are responsible for the 
resorption, or breakdown, of bone. Where the plasma membrane of osteoclasts contacts 
bone matrix, it creates many projections named a ruffled border. Hydrogen ions are 
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pumped across the ruffled border and produce an acid environment that causes 
decalcification of the bone matrix. Alongside this, the osteoclasts also release enzymes 
that digest the protein components of the matrix. Osteoblasts assist in the resorption of 
bone by osteoclasts by producing enzymes that break down the thin layer of 
unmineralized organic matrix that covers the bone (6).  
1.4.2.2 Osteoblasts  
Osteoblasts come from mesenchymal precursors that undergo a well-defined 
program of gene expression as they progress through osteoblastic commitment, 
proliferation, and terminal differentiation (12). They have an extensive endoplasmic 
reticulum and numerous ribosomes, produce collagen and proteoglycans. Osteoblasts 
also form vesicles that accumulate calcium ions (Ca
2+
), phosphate ions (PO4
2-
), and 
various enzymes. The contents of these vesicles are released from the cell by exocytosis 
and are used to create hydroxyapatite crystals (6). Mature osteoblasts produce a 
particular extracellular collagen matrix that subsequently becomes mineralized by 
deposition of these hydroxyapatite crystals (12).    
Ossification or osteogenesis is the formation of bone by osteoblasts. Elongated 
cell processes from osteoblasts link to cell processes of other osteoblasts through gap 
junctions. The osteoblasts then form an extracellular bone matrix that envelops the cells 
and their processes (6).  
Osteoblast-lineage cells, in addition to regulating bone formation, also regulate 
bone resorption through an elegant signaling axis which controls osteoclasts generation 
and activity (10).  
1.4.2.3 Osteocytes  
Osteoblasts are encased by the matrix that they themselves synthesize and 
become osteocytes (1). Osteocytes are relatively inactive cells compared to most 
osteoblasts (6). In spite of that, osteocytes play a major part in the determination and 
maintenance of bone structure (1).  
Osteocytes have a special function for triggering bone remodeling. These cells 
detect microcracks, mechanical strain, and the changes in the hormonal milieu of the 
bone. Osteocytes communicate with bone-lining cells, which initiate bone resorption 
and formation (9). The spaces occupied by the osteocyte cell bodies are called lacunae, 
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and the spaces occupied by the osteocyte cell processes are called canaliculi. In place of 
diffusing through the mineralized matrix, nutrients and gases can pass through the little 
amount of fluid surrounding the cells in the canaliculi and lacunae or pass from cell to 
cell through the gap junctions connecting the cell processes (6). Hence, osteocytes play 
a major part in coordinating bone remodeling (9).  
Table 3 - Bone cell types, morphological characteristics and functions. Adapted from Macromol. 
Biosci (2004), 4: 743-765. 
Bone cell type 
Morphological 
characteristics 
Functions 
Osteoclasts  
Polarized multinucleated 
cells. Hematopoietic 
origin.  
Bone resorption.  
Osteoblasts 
Polarized and cuboidal 
cells. Located at the bone 
surface with their 
precursors (where they 
form a tight layer of cells). 
Mesenchymal origin.  
Synthesis and regulation of 
bone extracellular matrix 
deposition and 
mineralization.  
Osteocytes  
Stellate shaped. Terminally 
differentiated osteoblasts. 
 
Mechanosensor cells of the 
bone. 
 
1.5 Molecular control of bone cell differentiation 
1.5.1 Osteoclastogenesis  
The osteoclast groups that quilt the cutting cone are derived from hematopoietic 
stem cells mainly present in the marrow and spleen. Osteoclastogenesis starts when a 
hematopoietic stem cell is stimulated to generate mononuclear cells, which then become 
committed pre-osteoclasts and enter the blood stream (10).  
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Two hematopoietic factors (expressed by osteoblasts and other cell types) are 
necessary and sufficient for osteoclastogenesis: the macrophage colony stimulating 
factor (M-CSF), and the receptor activator of nuclear factor κB ligand (RANKL) (11, 
13-15). Other authors suggested that osteoclastogenesis is also dependent on the 
expression of several genes, including the AP-1 member c-fos, micropthalmia-
associated transcription factor (MITF), and nuclear factor of activated T cells, 
calcineurin dependent 1 (NFAT-c1) (10, 15). Both, M-CSF and RANKL are required to 
induce expression of genes that typify the osteoclast lineage, including those encoding 
tartrate-resistant acid phosphatase (TRAP), cathepsin K (CATK), calcitonin receptor 
(CTR) and β3-integrin (or vitronectin receptor, VNR), leading to the development of 
mature osteoclasts (11, 16). M-CSF is believed to be critical for the proliferation of the 
osteoclast progenitors, while RANKL is membrane bound and directly controls the 
differentiation process by activating the receptor’s activator of nuclear factor κB 
(RANK), which is expressed on the cell surface of mononuclear hematopoietic 
osteoclast precursors to trigger osteoclast formation (1, 13). Thus, the activation of 
RANK by its ligand leads to the expression of osteoclast-specific genes during 
differentiation, the activation of resorption by mature osteoclasts, and their survival and 
participation in new rounds of bone degradation at neighboring sites (11). The 
circulating precursors leave the peripheral circulation at or near the site to be resorbed, 
and fuse with one another to form a multinucleated immature osteoclast. The success in 
the production of the immature osteoclast is associated with the initiation of TRAP 
expression, which is used later in more mature cells to assist in bone resorption. 
Additional differentiation of the immature osteoclast happens only under the continued 
presence of RANKL and once the transition to mature osteoclast is reached, the bone-
resorbing activity and survival of the mature osteoclast are regulated by RANKL (10). 
The mature, multinucleated osteoclast is activated by signals, which leads to the 
beginning of bone remodeling. The osteoclast cell body is polarized, and in response to 
activation of RANK by its ligand, it undergoes internal structural changes that prepare it 
to resorb bone, such as the rearrangements of the actin cytoskeleton and formation of a 
tight junction between the bone surface and basal membrane to form a sealed 
compartment (11).  The mature osteoclast engages in bone resorption through peripheral 
attachment to the matrix, employing the β3 integrin, which creates a microcompartment 
between the ruffled basal border of the cell and the bone surface. H
+
 ions are pumped 
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into the compartment by the osteoclast to solubilize the mineral component, followed by 
protease degradation of the organic matrix (10). Collagen fragments and solubilized 
calcium and phosphate (degradation products) are processed inside the osteoclast and 
released into the circulation (11). 
  The osteoblastic cells also produce a soluble protein that blocks osteoclast 
formation and bone resorption, the osteoprotegerin (OPG). It acts as decoy receptor by 
blocking RANKL binding to its cellular receptor RANK. OPG overexpression impairs 
osteoclast production, whereas OPG deletion results in enhanced remodeling of bone. 
Expression of RANKL and OPG is therefore coordinated to regulate bone resorption 
and density positively and negatively by controlling the activation state of RANK and 
osteoclasts (11, 13).  
 RANK signaling is mediated by cytoplasmic factors that activate downstream 
signaling pathways that control RANK’s various functions. Some of the pathways are c-
Jun N-terminal kinase (JNK) and Nuclear Factor Kappa-B (NFkB) (1, 11).  
The osteoblast lineage plays an essential role in each step of this process (13).   
  
1.5.2 Osteoblastogenesis  
After resorption of a bone unit by the osteoclast, osteoblasts are then attracted to 
the surface of bone to begin refilling the pit that remains. As osteoclasts resorb bone 
matrix, they release factors that have been embedded in the bone matrix during bone 
formation. These factors may need some processing by the osteoclast to be activated 
before secretion, and may then stimulate bone formation by the osteoblast (13).  
Osteoblast development follows a different way, beginning with the local proliferation 
of mesenchymal stem cells residing in the marrow (10). During skeletal development 
osteoblast differentiation and deposition of bone matrix occurs, and involves 
spatiotemporal coordination of interaction among diverse endocrine, paracrine and 
autocrine factors. Osteoblast differentiation is stimulated by several factors at different 
stages of differentiation (1). Expression of the transcription factors runt-related 
transcription factor-2 (Runx2), distal-less homeobox-5 (Dlx5), and msh homeobox 
homologue-2 (Msx2) is required to push the precursor cells toward the osteoblast 
lineage and away from the adipocyte, myocyte, and chondrocyte lineages also yielded 
by the mesenchymal stem cell (10). Runx2 is frequently described as the master 
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regulator of osteoblastogenesis. It acts throughout the induction, proliferation and 
maturation of osteoblasts and regulates expression of many osteoblast genes. Numerous 
signaling pathways and transcription factors that influence osteoblastogenesis do so by 
influencing the production or activity of Runx2 (12). The committed pre-osteoblast 
expresses type I collagen and bone sialoprotein (Bsp). Further differentiation of the pre-
osteoblast into a mature, bone-forming osteoblast phenotype requires the expression of 
Runx2, osterix (Osx), and several components of the Wnt signaling pathway (10). Osx 
is a zinc finger transcription factor expressed in osteoblasts and, like Runx2, ir required 
for bone formation (12).  The mature osteoblast expresses the matrix proteins type I 
collagen (ColI) and osteocalcin (OC) and a key enzyme in the mineralization process, 
alkaline phosphatase (ALP). As a row of active osteoblasts secretes unmineralized 
matrix (osteoid) and advances away from the bone surface, a small number of cells fall 
behind and become incorporated into the matrix (10). These osteoblasts begin to 
generate long cytoplasmic processes to remain in communication with surrounding cells 
and upregulate expression of E11, an early osteocyte marker. At this point, the cells are 
considered immature osteocytes. As the matrix matures and mineralizes, and the osteoid 
seam moves further away, the osteocyte becomes entombed in a bony matrix and begins 
to mature and express a new set of genes, including dentin matrix protein-1 (DMP-1) 
and matrix extracellular phosphoglycoprotein (MEPE) (10).  
Some authors suggested that Cbfa1 gene is essential for osteoblasts differentiation 
and bone formation (17). More recently, Zuo C., et al (9) affirmed, and Sims N., et al 
(13) supported, that osteoblasts are regulated by signals derived from autocrine, 
paracrine, various cell-cell interactions, and from the systemic level, including the 
endocrine and nervous systems. These signals include transforming growth factor-β 
(TGF-β), bone morphogenetic proteins (BMPs),  Wnts, Notch, Eph-Ephrin interaction, 
parathyroid hormone/parathyroid hormone-related peptide (PTH/PTHrP), and the 
leptin-serotonin-sympathetic nervous system pathway (9, 13, 14).   
 
1.6 Bone formation and bone remodeling  
Bone formation during fetal life and until the end of puberty occurs by two 
mechanisms: intramembranous and endochondral ossification. The terms describe the 
tissues in which bone formation takes place: intramembranous ossification in 
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connective tissue membranes and endochondral ossification in cartilage (6). The 
longitudinal growth of long bones is based on osseous transformation of the cartilage in 
the growth plate, called endochondral ossification. Most flat bones are formed through 
intramembranous ossification, whereby bone formation results from direct 
transformation of fibrous matrix into osteoid (extracellular matrix), followed by 
mineralization (deposition of calcium phosphate salts). Intramembranous ossification 
also accounts for the subperiosteal bone formation of long bones, which is the basis of 
the appositional growth and widening of long bones. Endochondral ossification ceases 
by the end of puberty and appears later only exceptionally and under pathologic 
conditions, for example during the healing of bone fractures. The intramembranous 
appositional growth of long bones continues, albeit at a slower rate, throughout the 
normal life span (7).  
Bone is a dynamic tissue that is constantly formed and resorbed in response to 
changes in mechanical loading, altered serum calcium levels and in response to a wide 
range of paracrine and endocrine factors (13). Bone is capable of adapting its structure 
to mechanical stimuli and repairing structural damage through the process of 
remodeling, which removes and replaces discrete, measurable “packets” of bone. These 
replacement packets of bone, or bone structural units (BSUs), comprise secondary 
osteons. Bone is remodeled by groups of cells derived from different sources, which are 
collectively called the basic multicellular unit (BMU) (10). The BMU is a temporary 
anatomic structure that together with a canopy composed of bone-lining cells, and the 
associated capillary networks form a functional structure known as the bone remodeling 
compartment (9, 10). Within the BMU, cellular activity is matched, a principle that the 
amount of bone destroyed by osteoclasts in the BMU is equal to the amount of bone 
formed by osteoblasts. Matsuo K., et al (14) refer that bone remodeling had been 
described as a “bone remodeling cycle” consisting of activation, resorption, reversal, 
and formation phases. However, it is said that, in terms of osteoclast-osteoblast 
communication, it may be more convenient to describe bone remodeling as occurring in 
three phases: initiation, transition, and termination remodeling. (for an extensive review, 
see reference (14)). Thus, remodeling is a coordinated action between osteoclasts (cells 
that destroy bone) and osteoblasts (cells that form bone) as well as osteocytes within the 
bone matrix and osteoblast-derived lining cells that cover the surface of bone (13). In 
normal adults there is a balance between the amount of bone resorbed and formed. 
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During resorption, the osteoclasts release local factors from the bone, which might have 
two effects: inhibition of osteoclast function and stimulation of osteoblast activity. 
Furthermore, osteoclasts themselves produce and release factors that have a negative 
regulatory effect on their activity, and enhance osteoblast function (8).   
For a better understanding of this process, see Figure 1.   
1.7 Factors affecting bone growth 
The bones in any skeleton usually reach a certain thickness, length, and shape. The 
potential shape and size of a bone and an individual’s final adult height are determined 
genetically, but hormonal and exogenous factors can seriously modify the expression of 
those genetic factors (6, 18).  
1.7.1 How do exogenous factors affect bone growth? 
Exogenous factors that adversely affect bone growth include cigarette smoking, 
physical handicaps, certain medications and nutrition (18). Because bone growth 
requires osteoblast proliferation, any metabolic disorder that affects the rate of cell 
proliferation or the production of collagen and other matrix components affects bone 
growth, as well as the availability of calcium or other minerals needed in the 
mineralization process. Malnutrition during the time of bone growth can cause seriously 
problems (6). Certain vitamins are important in very specific ways to bone growth. 
Vitamin D is necessary for the normal absorption of calcium from the intestines. The 
body can either synthesize or ingest vitamin D. Vitamin C is necessary for collagen 
synthesis by osteoblasts. Normally, as old collagen breaks down, new collagen is 
synthesized to replace it (6).  
1.7.2 How do hormones affect bone growth?  
Hormones are paramount in bone growth. The growth hormone from the anterior 
pituitary increases general tissue, including overall bone growth, by stimulating 
interstitial cartilage growth and appositional bone growth. The thyroid hormone is also 
required for normal growth of all tissues, including cartilage; therefore, a decrease in 
this hormone can result in decreased size of the individual. Sex hormones also influence 
bone growth. Estrogen (a class of female sex hormones) and testosterone (a male sex 
hormone) initially stimulate bone growth, which accounts for the burst of growth at the 
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time of puberty, when the production of these hormones increases. Both hormones also 
stimulate ossification of epiphyseal plates, however, and thus the cessation of growth 
(6). 
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Figure 1 - The bone remodeling process - Osteoblasts arise from mesenchymal precursors [1] 
and are responsible for produce mineralized bone matrix [bone formation]. In addition to 
regulating bone formation, they also regulate bone resorption by generating and activating 
osteoclasts activity [2]. Osteoclasts originate by the differentiation of monocyte/macrophage 
precursor’s cells [4]. As osteoclasts resorb bone matrix, they liberated matrix bound growth 
factors that then stimulate osteoprogenitor cells proliferation and bone formation by the 
osteoblast [3].  
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1.8 Epilepsy  
Damjanov I. (7) characterized epilepsy in his book “Pathology for the Health 
Professions” as a group of diseases that lead to recurrent seizures. Seizures are typically 
characterized by convulsions, which are described as uncoordinated twitching of 
muscles and spastic contractions.  Also, epileptic attacks may include abnormal motor 
activity, short periods of altered consciousness, altered sensory phenomena, or 
inappropriate behavior. All these manifestations of epilepsy are believed to result from 
abnormal synchronized electrical activity of the brain (7). Löscher W., et al (19) stated 
that epilepsy is one of the most common neurologic disorders, affecting about 4% of 
individuals over their lifetime.  
1.8.1 Epilepsy and bone metabolism 
 Epilepsy is a chronic condition that may affect individuals for years (20). The 
evidence gathered over the past years show a strong link between long-term use of 
AEDs and disturbed bone metabolism, resulting in decreased bone mineral density 
(BMD) and an increased risk of fractures (21-24). Besides, AED therapy has been also 
associated with vitamin D deficiency and altered bone turnover (25). The propensity to 
fracture bones is increased in patients with epilepsy. Some are directly due to seizure or 
to falls, with or without associated seizures (26). Reduced bone accumulation in 
individuals with epilepsy and progressive bone loss caused by AEDs, may increase 
susceptibility to fractures (27). Risk of fractures after a few years of taking AEDs is two 
to six times greater in those who take it than in general population (28). Fractures can 
have catastrophic effects on the lives of patients with epilepsy (26).     
1.8.2 Epilepsy and AEDs: should we be concern? 
The mechanism of AED-related bone disease remains controversial (23, 29). 
Antiepileptic-induced bone disease has a heterogeneous spectrum of severity (30).  
AEDs that induce the cytochrome P450 enzyme system are most commonly 
associated with abnormalities in bone (31-33). Carbamazepine is an inducer of the 
cytochrome P450 enzyme system. On the other hand, valproic acid is an inhibitor of the 
cytochrome P450 enzyme system (34). Enzyme-inducing AEDs alter vitamin D 
concentrations and may lead to the reduction of bone mass, although, nonenzyme 
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inducing AEDs may also affect bone by possibly altering osteoblastic function (18, 25, 
27, 35). Notwithstanding, studies find conflicting results when evaluating its effect on 
bone and mineral metabolism (34, 36).  
There are only a few studies of the effects of the other newer agents (gabapentin, 
lamotrigine and topiramate) on bone mineralization, so that, no conclusions can be 
drawn (18). However, Beerhorst K., et al (37) affirmed that not only the older AEDs but 
also the newer are associated with negative effects on bone metabolism. Gabapentin 
does not induce or inhibit hepatic enzymes, however, a few authors suggested that this 
drug can induce bone loss. The same scenario happens with lamotrigine (24, 38). 
Topiramate, for example, is a weak carbonic anhydrase inhibitor that may result in 
clinically significant metabolic acidosis and adverse effects on bone health. However, 
limited information is available (39).  
At the present, the neurologists can choose from over 20 different AEDs, including 
older or first generation drugs such as carbamazepine, valproic acid, phenytoin and 
phenobarbital, and new or second generation drugs such as lamotrigine, topiramate, 
gabapentin, levetiracetam, vigabatrin and tiagabine (19, 40).  
During recent years, a great number of new AEDs have been marketed worldwide, 
but the proportion of patients failing to respond to drug treatment has not been changed 
to any significant level. Furthermore, none of the old or new AEDs appears to represent 
a “cure” for epilepsy or an effective means for preventing epilepsy or its progression. 
Consequently, new concepts and original ideas for developing AEDs are urgently 
needed (19).   
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1.9 Outline and objectives of this thesis  
Bone is the dynamic tissue comprising functionally distinct and unique cell 
populations that support the biochemical, mechanical and structural integrity of the 
skeleton. Bone undergoes remodeling, a continuing process of bone formation and 
resorption (41).  The precise balance between bone formation and resorption is critical 
for the maintenance of bone mass density and systemic mineral homeostasis (9).  
Epilepsy is one of the most common neurologic disorders, as well as a major public 
health issue. Current antiepileptic drugs are often accompanied by persistent side effects 
(19). Evidence shows that there is an association between long-term use of AEDs and 
disturbed bone metabolism. This is particularly problematic for people with epilepsy as 
their propensity to fractures is already elevated due to other drug side-effects, co-
existing neurological deficits and seizure-related falls (21).    
 
Taking into account all these factors, the main goal of this thesis was to perform an 
in vitro study that helps to characterize the effects of five different AEDs 
(Carbamazepine, Gabapentin, Lamotrigine, Topiramate and Valproic Acid) on bone 
metabolism. This goal was achieved through the following tasks: 
1. Isolation of human osteoclastic and osteoblastic cells from healthy individuals; 
2. Evaluation of the effect of five different AEDs in human osteoclastic and 
osteoblastic cell cultures;  
3. Analysis of the influence of signaling pathways important for osteoclastogenesis 
and osteoblastogenesis in cellular responses of bone cells to AEDs.  
Lastly, this thesis ends with Chapter 6 which describes the main conclusions drafted 
from this study, as well as possible future directions that should be addressed in order to 
answer some of the main questions that this work has raise. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 – Effects of AEDs on PBMC cultures 
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2.1 Introduction  
Osteoclasts are specialized cells derived from the monocyte/macrophage 
hematopoietic lineage that develop and adhere to bone matrix, then secrete acid and 
lytic enzymes that degrade it in a specialized, extracellular compartment (11).  So that 
resorption happens, osteoclasts attach to the bone surface by means of integrins, secrete 
acid hydrolyses, and resorb bone matrix. Because of the dynamic nature of bone, 
constant remodeling occurs (41). It was documented that AEDs induce disturbances on 
bone integrity (33). Hereupon, we performed an in vitro study with human osteoclasts in 
order to try to understand how AEDs these bone cells. 
2.1.1 Aims 
As discussed in Chapter 1, osteoclasts are responsible for bone resorption. This 
chapter describes the way we cultured osteoclastic cells, and the main aim was to 
investigate the effects of five different AEDs on the differentiation and function of 
human osteoclasts. We also tried to analyze the influence of signaling pathways 
important for osteoclastogenesis in cellular responses of bone cells treated with AEDs.  
2.2 Material and methods  
2.2.1 The culture of osteoclastic cells  
Peripheral blood mononuclear cells (PBMC) were isolated from blood of 25-35 
years old healthy male donors, after informed consent, as previously described (42). 
Shortly, after dilution with phosphate-buffered saline (PBS) (2:1), blood was applied on 
top of Ficoll-Paque™ PREMIUM (GE Healthcare Bio-Sciences). Samples were 
centrifuged at 400 g for 30 minutes and PBMC were collected at the interface between 
Ficoll-Paque and PBS. Cells were washed twice with PBS. On average, for each 90 mL 
of processed blood about 450x10
6
 PBMC were obtained. PBMC, seeded at 
1.5x10
6
cells/cm
2
, were maintained in α-minimal essential medium (α-MEM) 
supplemented with 30% human serum (from the same donor from which PBMC were 
collected), 100 IU/ml penicillin, 2.5 µg/ml streptomycin, 2.5 µg/ml amphotericin B, 2 
mM L-glutamine and the osteoclastogenic inducers M-CSF (25 ng/mL) and RANKL 
(40 ng/mL) (11, 43).  
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Cell cultures were performed in the absence (control) or presence of five different 
Antiepileptic Drugs (AEDs). The tested AEDs (Carbamazepine, Gabapentin, 
Lamotrigine, Topiramate and Valproic Acid) were used at five different concentrations 
within the range of 10
-8
-10
-4
 M. Cell cultures were then characterized throughout a 21 
day period, at days 7, 14 and 21, using the following parameters:  
 
1. Protein quantification, 
2. TRAP activity, 
3. Number of TRAP-positive multinucleated cells, 
4. Presence of cells with actin rings and expressing vitronectin and calcitonin 
receptors, 
5. Apoptosis rate.  
 
Cell cultures were incubated at 37ºC in a 5% CO2 humidified atmosphere. Culture 
medium was replaced once a week and the AEDs were renewed at each medium 
change. 
Next, PBMC were treated with the minimum concentration of each AED that 
elicited a significant effect on cellular response, and were further characterized for: 
  
a. Calcium phosphate resorbing ability, 
b. Involvement of some osteoclastogenesis-related signalling pathways on cellular 
response.  
 
The AEDs tested were renewed at each medium change. Cell cultures were 
incubated at 37ºC in a 5% CO2 humidified atmosphere.  
 
2.2.2 Osteoclastic cultures characterization 
 Cell cultures were then characterized throughout a 21 day period, at days 7, 14 
and 21, for the following parameters: 
 
1. Protein quantification – Total protein content of cell cultures was quantified at 
days 7, 14 and 21 by Bradford’s method (44). Firstly, PBMC cultures were washed 
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twice with PBS and then they were solubilized with 0.1 M NaOH.  Coomassie® Protein 
Assay reagent (Fluka) was added to the cell cultures and the absorbance at 595nm was 
determined in an ELISA plate reader (Synergy HT, Biotek). Results were expressed as 
mg/mL. 
 
2. TRAP activity – TRAP activity was determined by the para-
nitrophenilphosphate (pNPP) hydrolysis assay, at days 7, 14 and 21, as previously 
described (45). Shortly, after being washed twice with PBS and solubilized with 0.1% 
(V/V) Triton X-100, samples were incubated with 22.5 mM pNPP prepared in 0.225 M 
sodium acetate, 0.3375 M KCl, 0,1% Tx-100, 22.5 mM sodium tartarate and 0.225 mM 
iron chloride (pH = 5.8) for 1 hour at 37ºC. The reaction was stopped with 5 M NaOH, 
and the absorbance of the samples at 400 nm was measured in an ELISA plate reader 
(Synergy HT, Biotek). Results were normalized to total protein content of cultures and 
expressed as nmol/min/µgprotein.  
 
3. Number of TRAP-positive multinucleated cells - At days 14 and 21, PBMC 
cultures were washed twice with PBS, fixed with 3.7% formaldehyde for 15 min, rinsed 
with distilled water, and stained for TRAP with Acid Phosphatase, Leukocyte kit 
(Sigma), according to the manufacturer’s instructions. Briefly, cells were incubated with 
0.12 mg/ml naphtol AS-BI, in the presence of 6.76 mM tartarate and 0.14 mg/ml Fast 
Garnet GBC at 37ºC for 1 h in the dark. After incubation, cell layers were washed and 
stained with hematoxylin. After being washed with water, cells were visualized by light 
microscopy (Nikon TMS phase contrast microscope). Multinucleated (>2 nuclei) and 
TRAP-positive (purple/dark red) cells were counted. 
 
4. Presence of cells with actin rings and expressing vitronectin and calcitonin 
receptors - PBMC cultures, at day 21, were washed twice with PBS and after being 
fixed with 3.7% para-formaldehyde for 15 minutes, cells were permeabilized with 0.1% 
(V/V) Triton X-100 for 5 minutes. Cells layers were stained for F-actin with 5 U/mL 
Alexa Fluor
®
 647-Phalloidin (Invitrogen), and for vitronectin receptors (VNR) and 
calcitonin receptors (CTR) with 50 µg/mL mouse IgGs anti-VNR and IgGs anti-CTR 
(R&D Systems), respectively. Anti-VNR and anti-CTR detection was performed with 
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2µg/mL Alexa Fluor
®
 488-Goat anti-mouse IgGs. Cultures were observed by Confocal 
Laser Scanning Microscopy (CLSM) (Leica TCP SP2 AOBS confocal microscope). 
 
5. Apoptosis Rate - Apoptosis was quantified by measuring caspase-3 activity. For 
that, cell cultures, at days 14 and 21, were washed twice with PBS and assessed for 
caspase-3 activity with EnzCheck® Caspase-3 Assay Kit #2 (Molecular Probes), 
according to the manufacturer’s instructions. Fluorescence was analysed at 496/520 nm 
(excitation/emission) in an ELISA plate reader (Synergy HT, Biotek). Results were 
presented as a % of activity (normalized with the corresponding total protein content 
value) compared to the control. 
 
Next, PBMC were treated with the minimum concentration of each AED that 
elicited a significant effect on cellular response, and were further characterized for: 
 
a. Calcium phosphate resorbing ability – PBMC cultures were performed on BD 
BioCoat™ Osteologic™ Bone Cell Culture Plates (BD Biosciences), for 21 days. After 
that culture period, cells were removed with 6% NaOCl and 5.2% NaCl, following 
manufacturer’s protocol. The remaining calcium phosphate layers were visualized by 
phase contrast light microscopy (Nikon TMS phase contrast microscope). Resorption 
lacunae were identified and total resorbed area was quantified with ImageJ 
1.41software.  
 
b. Involvement of some osteoclastogenesis-related signalling pathways on 
cellular response - PBMC cultured for 7, 14 and 21 days were treated with inhibitors of 
signalling pathways involved in the osteoclastogenic response (11). U0126, a MEK 
(methyl ethyl ketone) signalling pathway inhibitor, was tested at 1 µM. PDTC, a NFkB 
(nuclear factor kappa-B) signalling pathway inhibitor, was used at 10 µM. GO6983, a 
PKC (protein kinase C) signaling pathway inhibitor, was tested at 5µM. Finally, 
SP600125, a JNK (c-Jun N-terminal kinase) signalling pathway inhibitor, was used at 
10M. Cultures were assessed for total protein content and for TRAP activity. 
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2.2.3 Statistical analysis  
Data presented in this work is the outcome of experiments performed with cells 
from two different blood donors. Three replicas of each condition were made for each 
experiment. Data was evaluated using a two-way analysis of variance (ANOVA) and no 
significant differences in the pattern of the cell behavior were observed. Statistical 
differences found between control and experimental conditions were determined by 
Bonferroni’s method. For values of P ≤ 0.05, differences were considered statistically 
significant. Data is expressed as the mean ± standard deviation. 
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2.3PBMC results 
2.3.1 TRAP activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 shows that, at control conditions, TRAP activity clearly increased until day 
14. Between days 14 and 21, TRAP activity increased more slowly. The different AEDs 
had the ability to modulate the osteoclastogenic process. The majority of the tested 
AEDs negatively modulated it, leading to a dose-dependent decrease of TRAP activity. 
At lower doses (10
-8
M) TRAP activity seems not to be affect by the presence of any 
AED. The decrease became statistically significant at 10
-7
M gabapentin and lamotrigine 
(~19.95 and 24.92%, respectively) and 10
-6
M carbamazepine and topiramate (~16.70% 
and 27.65%, respectively). Valproic acid appeared as an exception since at lower doses 
(10
-7
M) caused an increase of TRAP activity (~29.02%). For concentrations higher than 
that, a dose-dependent decrease on cell response was observed. 
Figure 2 - TRAP activity of PBMC cultures maintained in the presence of recombinant M-CSF and 
RANKL, in the absence (negative control) or supplemented with different AEDs, cultured for 7, 14 
and 21 days. * Significantly different from the control. 
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2.3.2 Number of TRAP-positive multinucleated cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results obtained for TRAP+ multinucleated cells (Figure 3), after 14 and 21 
days of culture, followed the same profile observed for TRAP activity. Briefly, at lower 
doses (10
-8
M) the number of TRAP+ multinucleated cells seems not to be affected by 
the presence of any AED. Also, supplementation with 10
-7
M of Carbamazepine and 
Topiramate seems not to affect this number. The decrease became statistically 
significant at 10
-7
M gabapentin and lamotrigine (~21.78% and 15.20%, respectively) 
and 10
-6
M carbamazepine and topiramate (~18.93% and 20.18%, respectively). 
Valproic acid appeared as an exception since at lower doses (10
-7
M) caused an increase 
of number of TRAP+ multinucleated cells (~35.94%), as noticed in TRAP activity 
results. For concentrations higher than that, a dose-dependent decrease on cell response 
was observed. 
Figure 3 - Number of TRAP+ multinucleated cells on PBMC cultures maintained in the presence 
of recombinant M-CSF and RANKL, in the absence (negative control) or supplemented with 
different AEDs. * Significantly different from the control. 
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2.3.3 Presence of cells with actin rings and expressing 
vitronectin and calcitonin receptors  
 
 
 
 
 
 
 
 
 
At day 21, PBMC cultures showed cells displaying osteoclastic features, that is, 
cells with actin rings and expressing vitronectin and calcitonin receptors. The amount of 
osteoclastic cells in the different conditions was somehow correlated with the 
qualitative results observed for TRAP activity. Figure 4 shows representative images of 
cultures maintained in control conditions or treated with Valproic acid.  
 
 
 
 
 
 
 
 
Negative 
Control 
Valproic Acid 10
-7
M 
Valproic Acid 10
-7
M Negative 
Control 
V 
N 
R 
C 
T 
R 
Figure 4 - Representative images of PBMC cell cultures visualized by confocal laser scanning 
microscopy (CLSM). Cells were stained blue for F-actin and green for Vitronectin Receptors (VNR) 
and Calcitonin Receptors (CTR). White bars represent 120 µm. 
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2.3.4 Apoptosis rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 shows that caspase-3 activity remained similar in the three culture 
periods tested, in all tested conditions. Supplementation with carbamazepine, 
gabapentin, lamotrigine and topiramate elicited a dose-dependent increase of caspase-3 
activity. Supplementation with valproic acid caused a decrease of caspase-3 activity at 
10
-6
M concentration, while at 10
-4
M an increase on cell response was observed.   
 
 
 
 
Figure 5 - Caspase-3 activity on PBMC cultures maintained in the presence of recombinant M-
CSF and RANKL and treated with different AEDs. * Significantly different from the control. 
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2.3.5 Calcium phosphate resorbing ability  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 6 and 7 show that the presence of Valproic acid induced an increase on the 
total resorbed area (~70.95%). However, the other drugs elicited a decrease on the 
resorbing ability. Topiramate was the one that most elicited this decrease (~50.10%), 
while the remaining molecules caused a similar response (~32.70% lower than in the 
control). 
Negative Control  Carbamazepine 10
-6
M   Gabapentin 10
-7
M  
Lamotrigine 10
-7
M Topiramate 10
-6
M  Valproic Acid 10
-7
M  
Figure 6 - Calcium phosphate resorbing ability of PBMC cultures maintained in the presence of 
recombinant M-CSF and RANKL, in the absence (negative control) or treated with different AEDs. 
Figure 7 - Total resorbed area of PBMC cultures maintained in the presence of recombinant M-CSF 
and RANKL, in the absence (negative control) or treated with different AEDs. * Significantly different 
from the control. 
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2.3.6 Involvement of some osteoclastogenesis-related signaling 
pathways on cellular response 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the control, TRAP activity decreased in the presence of all tested signaling 
pathways inhibitors, especially in the case of PDTC that significantly abolished TRAP 
activity to values barely detectable. Comparatively, the presence of U0126 seemed not 
to affect the cellular response in cells cultures treated with gabapentin, while cultures 
supplemented with carbamazepine exhibited a higher inhibition. When supplemented 
with AEDs, the presence of PDTC also abolished TRAP activity to low values.  
GO6983 did not significantly affect the cellular response in cell cultures treated with 
lamotrigine and valproic acid, while in the presence of the remaining AEDs it elicited a 
decrease on TRAP activity slightly higher than the one observed in the control. 
Supplementation with SP600125 did not affect the behavior of cultures maintained in 
the presence of carbamazepine, while those treated with lamotrigine, topiramate and 
valproic acid exhibited a significantly higher inhibition than in the control. 
Figure 8 - TRAP Activity of PBMC cultures performed in the presence of different AEDs. Cell 
cultures were supplemented with different osteoclastogenic-related signaling pathways, namely 
U0126 (MEK inhibitor), PDTC (NFkB inhibitor), GO6983 (PKC inhibitor) and SP600125 (JNK 
inhibitor). * Significantly different from the control.  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 – Effects of AEDs on osteoblastic cell cultures   
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3.1 Introduction  
The most important function of osteoblasts is to create mineralized bone tissues. 
These cells display various phenotypic markers such as high alkaline phosphatase 
(ALP) activity and synthesize collagenous and noncollagenous bone matrix proteins 
which include osteocalcin (46). The coordinated actions of osteoblasts and osteoclasts 
result in bone turnover or remodeling. Unfortunately, some AEDs can result in 
metabolic bone disease, affecting this balance between bone formation and resorption. 
Adverse effects of AEDs in osteoblast-like cells have been reported (41). In order to try 
to understand how AEDs affect bone cells, we performed an in vitro study with 
osteoblasts.    
3.1.1 Aims 
As discussed throughout Chapter 1, osteoblast-lineage cells, in addition to 
regulating bone formation, also regulates bone resorption via an elegant signaling axis 
that controls osteoclast differentiation and activity (10).  
This chapter describes the way we cultured osteoblastic cells, and the main aim 
was to investigate the effects of five different AEDs on the differentiation and function 
of human osteoblasts. We also tried to analyze the influence of signaling pathways 
important for osteoblastogenesis in cellular responses of bone cells treated with AEDs.  
3.2 Material and methods  
3.2.1 The culture of osteoblastic cells 
Osteoblasts were obtained from femur heads of patients (25-45 years old) 
undergoing orthopaedic surgery procedures, after informed consent, as previously 
described (47). Briefly, bone was broken in small pieces, which were maintained in α-
MEM containing 10% fetal bovine serum, 100 IU/mL penicillin, 2.5 μg/mL 
streptomycin, 2.5μg/mL amphotericin B and 50 μg/mL ascorbic acid. At about 70-80% 
confluence, cells were enzymatically detached with 0.05% trypsin and 0.5 mM 
ethylenediamine tetraacetic acid (EDTA). Thereafter, they were seeded at 10
4
cells/cm
2
.  
Cell cultures, performed in the same culture medium mentioned above, were treated 
with 10 mM β-glycerophosphate (phosphate donor) and 10 nM dexamethasone 
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(osteogenic stimulator), and were maintained in the absence (control) or presence of 
five different AEDs, using five different concentrations  within the range of 10
-8
-10
-4
 M.  
Cell cultures were then characterized throughout a 21 day period, at days 7, 14 and 21, 
for the following parameters:  
 
1. Cellular proliferation/viability,  
2. ALP activity,  
3. Protein quantification,  
4. Histochemical staining of ALP,  
5. Visualization of cellular morphology by CLSM, 
6. Apoptosis rate.  
 
Cultures were incubated in a 5% CO2 humidified atmosphere at 37ºC. The culture 
medium was replaced once a week and the AEDs were renewed at each medium 
change. 
Next, osteoblasts were treated with the minimum concentration of each AED that 
elicited a significant effect on those parameters, and were further characterized for: 
  
a. Expression of osteoblast-related genes 
b. Involvement of some osteoblastogenesis-related signaling pathways on cellular 
response 
3.2.2 Osteoblastic cultures characterization  
Cell cultures were then characterized throughout a 21 day period, at days 7, 14 
and 21, for the following parameters:  
 
1. Cellular proliferation/viability – The cellular proliferation/viability assessment 
was performed by MTT (3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide) assay. Cell cultures were incubated with 5mg/mL MTT, at 37ºC for 3 hours. 
After that, the culture medium was removed and dimethyl sulfoxide (DMSO) was 
added. The absorbance was quantified at 550 nm in an ELISA plate reader (Synergy 
HT, Biotek). 
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2. ALP activity – ALP activity was determined by the pNPP hydrolysis assay, at 
days 7, 14 and 21, as previously described (48). Shortly, after being washed twice with 
PBS and solubilized with 0.1% (V/V) Triton X-100, samples were incubated with 22.5 
mM pNPP prepared in 0.15 M bicarbonate buffer (pH~10.3), for 1 hour at 37ºC. The 
reaction was stopped with 5 M NaOH, and the absorbance of the samples at 400 nm was 
measured in an ELISA plate reader (Synergy HT, Biotek). Results were normalized to 
total protein content of cultures and expressed as nmol/min/µgprotein. 
 
3. Protein quantification - Total protein content of cell cultures was quantified at 
days 7, 14 and 21 by Bradford’s method (44, 49), as described above. 
 
4. Histochemical staining of ALP – The method used was based on the hydrolysis 
of α-naphtyl phosphate by ALP and the precipitation of phosphate liberated by reaction 
with a salt, giving rise to the formation of a coloured product, as previously described 
(48). Cell cultures were fixed with 1.5% glutaraldehyde in 0.14 M sodium cacodylate 
buffer for 20 minutes and then washed with cacodylate buffer. After that, samples were 
incubated in the dark for 1 hour at 37ºC in 0.1 M Tris buffer (pH 10) containing 2 
mg/ml Na-α-naphtyl phosphatase and 2 mg/ml of Fast blue RR salt. The reaction was 
stopped by rinsing the samples with distilled water. A positive reaction is identified by 
the presence of a brown to black colour, in accordance with the amount of the enzyme. 
Cells were visualized by phase contrast light microscopy (Nikon TMS phase contrast 
microscope).  
 
5. Visualization of cellular morphology by CLSM - Cell cultures, at day 21, 
were washed twice with PBS and after being fixed with 3.7% para-formaldehyde for 15 
minutes, cells were permeabilized with 0.1% (V/V) Triton X-100 for 5 minutes. 
Cultures were stained for F-actin with 5 U/mL Alexa Fluor
®
 647-Phalloidin (Invitrogen) 
and for nuclei with 500 nM propidium iodide. They were then observed by Confocal 
Laser Scanning Microscopy (CLSM) (Leica TCP SP2 AOBS confocal microscope). 
 
6. Apoptosis rate – Apoptosis was quantified as described above. 
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Next, osteoblasts were treated with the minimum concentration of each AED that 
elicited a significant effect on those parameters, and were further characterized for:  
a. Expression of osteoblast-related genes - 21-day Cell cultures were assessed for 
the expression of the housekeeping gene glycerol-3-phosphate dehydrogenase 
(GAPDH) and the gene collagen type I (COL I) (1). RNA, 0.5 µg, was reverse 
transcribed and amplified (25 cycles) with the Titan One Tube RT-PCR System 
(Roche), with an annealing temperature of 55ºC. The primers used are listed on Table 2. 
PCR products were separated on an 1% (w/V) agarose gel, and the bands were analysed 
by densitometry with ImageJ 1.41 software. Values were normalized for the 
corresponding GAPDH value of each experimental condition.  
Table 4 - Primers Used on RT-PCR Analysis of Osteoblastic Cell Cultures 
Gene 5’ Primer 3’ Primer 
GAPDH 5’-CAGGACCAGGTTCACCAACAAGT-3’ 5’-GTGGCAGTGATGGCATGGACTGT-31’ 
COL I 5’-TCCGGCTCCTGCTCCTCTTA-3’ 5’-ACCAGCAGGACCAGCATCTC-3’ 
 
b. Involvement of some osteoblastogenesis-related signaling pathways on 
cellular response – Osteoblastic cells cultured for 7, 14 and 21 days were treated with 
inhibitors of signalling pathways involved in the osteoblastogenic response (50). 
U0126, a MEK signalling pathway inhibitor, was tested at 1 µM. PDTC, a NFkB 
signalling pathway inhibitor, was used at 10 µM. GO6983, a PKC signaling pathway 
inhibitor, was tested at 5µM. Finally, SP600125, a JNK signalling pathway inhibitor, 
was used at 10µM. Cultures were assessed for total protein content and for ALP 
activity. 
3.2.3 Statistical analysis  
Data presented in this work is the result of separated experiments performed with 
cells from different blood donors. Three replicas of each condition were made for each 
experiment. Data was evaluated using a two-way analysis of variance (ANOVA) and no 
significant differences in the pattern of the cell behaviour were observed. Statistical 
differences found between control and experimental conditions were determined by 
Bonferroni’s method. For values of P ≤ 0.05, differences were considered statistically 
significant. Data is expressed as the mean ± standard deviation. 
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3.3 Osteoblastic cells results  
3.3.1 Cellular proliferation/viability  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general, cellular proliferation / viability increased through the 21 days of 
culture. When supplemented with low doses (10
-8
M) of different AEDs, this behavior 
didn’t significantly change. At high doses, all AEDs cause a dose-dependent decrease 
on cellular proliferation / viability, especially observed at 21 days of culture.  
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Figure 9 - Osteoblasts proliferation and viability performed by the MTT assay. Cell cultures were 
treated with different AEDs. * Significantly different from the control. 
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3.3.2 ALP activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 shows that, without supplementation (negative control) with AEDs, 
ALP activity increased during the culture period (21 days). This increase was especially 
observed until day 14. Between days 14 and 21, ALP activity increased more slowly. 
The majority of the tested AEDs negatively modulated osteoblastogenesis, leading to a 
dose-dependent decrease of ALP activity. However, at lower doses (10
-8
M) ALP 
activity seemed not to be affect by the presence of any AED. The decrease became 
statistically significant at 10
-7
M gabapentin (~21.59%) and 10
-6
M carbamazepine and 
lamotrigine (~21.59% and 23.98% respectively). Topiramate and valproic acid appeared 
as an exception since at lower doses (10
-7
M and 10
-6
M respectively) caused an increase 
of ALP Activity (~15.91% and 23.00% respectively). For concentrations higher than 
that, a dose-dependent decrease on cell response was observed.  
Figure 10 - ALP activity of osteoblastic cell cultures maintained in the absence (control) or 
presence of different AEDs, cultures for 7, 14 and 21 days. * Significantly different from the 
control. 
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3.3.3 Histochemical staining of ALP 
 
 
 
 
 
 
 
Figure 11 shows that, cells were positively stained for ALP in all tested 
conditions. No significant differences were observed in the intensity of the staining 
among the different tested AEDs. Cells were uniformly spread in the culture well and 
exhibited the characteristic elongated morphology of this lineage.  
 
3.3.4 Visualization of cellular morphology by CLMS  
 
 
 
 
 
 
Figure 12 shows osteoblastic cell cultures stained for actin and nuclei and 
visualized by CLSM. Cells were uniformly distributed in the wells, with visible cell-to-
cell contacts, and displaying a proper elongated morphology. 
Figure 11 - Histochemical staining of ALP in osteoblastic cell cultures. 
Negative Control Topiramate 10
-7
M 
Figure 12 - Presence of multinucleated cells displaying actin rings and nuclei in osteoblastic cell 
cultures assessed by CSLM. Fluorescence images showing actin rings (green) and nuclei (red). White 
bars represent 120 µm. 
Negative Control Carbamazepine 10
-6
M Gabapentin 10
-7
M 
Lamotrigine 10
-6
M Topiramate 10
-7
M Valproic acid 10
-6
M 
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3.3.5 Apoptosis rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 shows that caspase-3 activity remained similar in the three culture 
periods tested, in all tested conditions. Supplementation with carbamazepine, 
lamotrigine, topiramate and valproic acid elicited a dose-dependent increase of caspase-
3 activity. Supplementation with gabapentin caused a decrease of caspase-3 activity at 
10
-6
M concentration, while at 10
-4
M an increase on cell response was observed.   
 
 
 
Figure 13 - Caspase-3 activity on osteoblastic cell cultures treated with different AEDs. * 
Significantly different from the control. 
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3.3.6 Expression of osteoblast-related genes  
 
 
 
 
  
 
 
 
 
 
 
 
Cell layer was assessed by RT-PCR, in order to verify the expression of the 
housekeeping gene GAPDH and the osteoblastic gene COL1. Cell cultures revealed 
expression of both genes, in the presence of AEDs. In the control, the expression of 
COL1 was low. However, when cell cultures were treated with carbamazepine, 
lamotrigine and topiramate the expression levels significantly decreased (56.44%, 
91.79% and 35.95% respectively). On the other hand, when cell cultures were treated 
with gabapentin and valproic acid, the expression levels significantly increased (96.15% 
and 183.30%, respectively).   
 
Figure 14 - Representative agarose gel of osteoblastic cell cultures. Densitometric analysis of RT-PCR 
products normalized by GAPDH.  1 – Negative control; 2 – Carbamazepine; 3 – Gabapentin; 4 –
Lamotrigine; 5 –Topiramate; 6- Valproic acid. 
Figure 15 - Expression of osteoblastic-associated genes. 
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3.3.7 Involvement of some osteoblastogenesis-related signaling 
pathway on cellular response 
 
 
 
 
 
 
 
 
 
 
 
 
In the control, ALP activity decreased in the presence of all tested signaling 
pathways inhibitors. Comparatively, the presence of U0126 seemed not to affect the 
cellular response in cells cultures treated with carbamazepine and topiramate, while 
cultures supplemented with gabapentin and valproic acid exhibited a higher inhibition. 
When supplemented with AEDs, the presence of PDTC also abolished ALP activity to 
low values, especially with lamotrigine and topiramate.  GO6983 elicited a decrease on 
ALP activity slightly higher than the one observed in the control. Supplementation with 
SP600125 did not affect the behavior of cultures maintained in the presence of 
lamotrigine, while those treated with carbamazepine exhibited a significantly higher 
inhibition than in the control. 
Figure 16 - ALP activity of osteoblastic cell cultures performed in the presence of different AEDs. Cell 
cultures were supplemented with different osteoblastogenic-related signaling pathways, namely 
U0126 (MEK inhibitor), PDTC (NFkB inhibitor), GO6983 (PKC inhibitor) and SP600125 (JNK 
inhibitor). * Significantly different from the control. 
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CHAPTER 4 – Effects of AEDs on co-cultured cells    
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 4.1 Introduction  
Osteoclasts are cells specialized in bone resorption and osteoblasts are bone-forming 
cells (47). In addition to the well-established role of osteoblasts in osteoclastogenesis, 
recent studies have shown that osteoclasts are not simply bone resorbing cells, but that 
they also regulate osteoblast functions positively and negatively (2). Osteoclast-
osteoblast interactions occur at various stages of differentiation, contributing to 
coupling of bone resorption and formation (14).  Communication pathways exist 
between each of these cell types and the osteocytes, which are embedded in the bone 
matrix (13). Hereupon, osteoclastic and osteoblastic cells were cultured together.  
4.2 Aims   
As discussed throughout Chapter 1, both epilepsy itself and treatment with AEDs 
has been recognized to have an adverse effect on bone metabolism. A proper balance 
between bone formation and resorption is crucial for a healthy bone tissue.  
It has been documented that in the normal bone microenvironment osteoclast-
osteoblast crosstalks appear to have a direct influence in bone formation events (45).  
This chapter describes the way we cultured both cell types together, and the main 
aim was the investigation of the effects of five AEDs, guarantying that all the 
information regarding osteoclast and osteoblast differentiation was related to the cellular 
crosstalks between both cell types, so that we can study how they influence each other 
and their functions. 
4.3  Material and methods 
4.3.1 The co-culture of osteoclastic and osteoblastic cells 
 Osteoblastic cells were seeded (1x10
3
cells/cm
2
) and cultured for 24 hours in the 
same conditions used for the culture of isolated osteoblastic cells.  After that, PBMC 
were added (1.5x10
6
cells/cm
2
) to the osteoblastic cells and co-cultures were maintained 
in the same conditions described for the PBMC cultures but in the absence of any 
osteoclastogenic or osteogenic stimuli. Thus, it was expected that all the information 
regarding osteoclast and osteoblast differentiation was related to the cellular crosstalks 
between both cell types.  
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Cell cultures were maintained in the absence (control) or presence of the five 
tested AEDs (10
-8
-10
-4
 M).  
Cultures were maintained at 37ºC in a 5% CO2 humidified atmosphere and were 
characterized throughout a 21 day period, at days 7, 14 and 21. Culture medium was 
replaced once a week and the AEDs were renewed at each medium change.  
Cellular response was evaluated through the same osteoclast and osteoblast 
parameters mentioned and described above for the corresponding isolated cell cultures:  
 
1. Protein quantification, 
2. TRAP activity, 
3. Number of TRAP + multinucleated cells, 
4. Calcium phosphate resorbing ability,  
5. ALP activity, 
6. Histochemical staining of ALP, 
7. Cellular morphology, 
8. Expression of osteoclast and osteoblast-related genes,  
9. Involvement of some osteoclast and osteoblastogenesis-related signaling 
pathways on cellular response.  
 
4.4  Statistical analysis 
Data presented in this work is the result of separated experiments performed 
with cells from different blood donors. Three replicas of each condition were made for 
each experiment. Data was evaluated using a two-way analysis of variance (ANOVA) 
and no significant differences in the pattern of the cell behaviour were observed. 
Statistical differences found between control and experimental conditions were 
determined by Bonferroni’s method. For values of P ≤ 0.05, differences were 
considered statistically significant. Data is expressed as the mean ± standard deviation. 
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4.5 Co-cultures results  
4.5.1 TRAP activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 shows that, at control conditions, TRAP activity clearly increased until 
day 14. Between days 14 and 21, TRAP activity increased more slowly. The different 
AEDs had the ability to modulate the osteoclastogenesis process. The majority of the 
tested AEDs negatively modulated osteoclastogenesis, leading to a dose-dependent 
decrease of TRAP activity. At lower doses (10
-8
M) TRAP activity seems not to be 
affect by the presence of any AED. The decrease became statistically significant at 10
-
7
M topiramate (~17.31%) and 10
-6
M carbamazepine and lamotrigine (~24.12% and 
10.98%, respectively). Gabapentin and valproic acid appeared as an exception since at 
lower doses (10
-7
M and 10
-6
M respectively) caused an increase of TRAP Activity 
(~27.84% and 21.37% respectively). For concentrations higher than that, a dose-
dependent decrease on cell response was observed. 
Figure 17 - TRAP activity of co-cultures maintained in the absence (negative control) or 
supplemented with different AEDs, cultured for 7, 14 and 21 days. * Significantly different from 
the control. 
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4.5.2 Number of TRAP-positive multinucleated cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general, the results obtained for TRAP+ multinucleated cells (Figure 18), after 
14 and 21 days of culture, followed the same profile observed for TRAP activity. 
Briefly, at lower doses (10
-8
M) the number of TRAP+ multinucleated cells seems not to 
be affected by the presence of any AED, except topiramate which caused a statistically 
significant decreased of number of TRAP+ multinucleated cells (~17.98%). The 
decrease became statistically significant at 10
-7
M carbamazepine (~15.60%) and 10
-6
M 
lamotrigine (~31.99%). Gabapentin and valproic acid appeared as an exception since at 
lower doses (10
-7
M and 10
-6
M respectively) caused an increase of number of TRAP+ 
multinucleated cells (~29.06% and 37.08%, respectively). For concentrations higher 
than that, a dose-dependent decrease on cell response was observed. 
Figure 18 - Number of TRAP+ multinucleated cells on co-cultures maintained in the absence 
(negative control) or supplemented with different AEDs. * Significantly different from the control. 
 
* 
* * 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* * 
* * 
* 
* * 
* 
* 
* 
* 
 
* 
 
* 
* * * 
* 
* 
Characterization of the effects of antiepileptic drugs on bone metabolism: In vitro studies with human 
osteoblastic and osteoclastic cells 
49 
 
4.5.3 Calcium phosphate resorbing ability  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 19 and 20 show that the presence of gabapentin and valproic acid 
induced an increase on the total resorbed area (~54.14% and ~37.71% respectively). 
However, the other drugs elicited a decrease on the resorbing ability. Lamotrigine was 
the one that most elicited this decrease (~38.91%).  
 
Negative Control Carbamazepine 10
-6
M Gabapentin 10
-7
M 
Topiramate 10
-6
M Lamotrigine 10
-6
M Valproic Acid 10
-6
M 
Figure 19 - Calcium phosphate resorbing ability of co-cultures maintained in the absence (negative 
control) or treated with different AEDs. 
Figure 20 - Total resorbed area of co-cultures maintained in the absence (negative control) or treated 
with different AEDs. * Significantly different from the control. 
* 
* 
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4.5.4 ALP activity  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 shows that, without supplementation (negative control) ALP activity 
increased during the culture period (21 days). This increase is especially observed until 
day 14. Between days 14 and 21, ALP activity increased more slowly. The majority of 
the tested AEDs negatively modulated osteoblastogenesis, leading to a dose-dependent 
decrease of ALP activity. At lower doses (10
-8
M) ALP activity seems not to be affect by 
the presence of any AED. The decrease became statistically significant at 10
-7
M 
gabapentin and topiramate (~18.79% and 23.58%, respectively). The decrease became 
statistically significant at 10
-6
M carbamazepine and lamotrigine (~19.12% and 21.73%, 
respectively). Valproic acid appeared as an exception since at lower doses (10
-6
M) 
caused an increase of ALP Activity (~34.98%). For concentrations higher than that, a 
dose-dependent decrease on cell response was observed.  
Figure 21 - ALP activity of co-culture cells maintained in the absence (control) or presence of 
different AEDs, cultures for 7, 14 and 21 days. * Significantly different from the control. 
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4.5.5 Histochemical staining of ALP  
 
 
 
 
 
 
 
 
Figure 22 shows that cells were positively stained for ALP in all tested 
conditions. No significant differences were observed in the intensity of the staining 
among the different tested AEDs. Cells were uniformly spread in the culture well and 
exhibited the characteristic elongated morphology of this lineage. 
 
 
 
 
 
 
 
 
 
Negative Control Carbamazepine 10
-6
M Gabapentin 10
-7
M 
Lamotrigine 10
-6
M Topiramate 10
-6
M Valproic Acid 10
-6
M 
Figure 22 - Histochemical staining of ALP in co-cultures. 
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4.5.6 Cellular morphology 
 
 
 
 
 
 
 
 
 
At day 21, co-cultures showed cells displaying osteoclastic features, that is, cells 
with actin rings and expressing vitronectin and calcitonin receptors, as well as few 
elongated cells only positive for actin staining. Figure 23 shows representative images 
of co-cultures maintained in the absence or presence of carbamazepine. 
 
 
 
 
 
 
 
Carbamazepine 
10
-6
M 
Negative 
Control 
Negative 
Control 
V 
N 
R 
C 
T 
R 
Carbamazepine 
10
-6
M 
Figure 23 - Representative images of co-cultures visualized by confocal laser scanning microscopy 
(CLSM). Cells were stained blue for F-actin and green for Vitronectin Receptors (VNR) and 
Calcitonin Receptors (CTR). White bars represent 120 µm. 
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4.5.7 Expression of osteoclast and osteoblast-related genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell layers were assessed by RT-PCR (Figure 24), in order to verify the 
expression of the housekeeping gene GAPDH and the genes CATK and COL1. The co-
cultures revealed expression of both genes, either in the absence or presence of AEDs 
(Figure 25). When cell cultures were treated with valproic acid the expression levels of 
CATK significantly increased (~45.02%). On the other hand, in the control, the 
expression of COL1 was low, and this was not significantly affected by the presence of 
gabapentin, lamotrigine and topiramate.  However, when cell cultures were treated with 
carbamazepine and valproic acid the expression levels significantly increased (~43.38% 
and 33.70%, respectively). 
* 
* * 
Figure 24 - Representative agarose gel of co-cultures. Densitometric analysis of RT-PCR products 
normalized by GAPDH.  1 – Negative control; 2 – Carbamazepine; 3 – Gabapentin; 4 –
Lamotrigine; 5 –Topiramate; 6 – Valproic acid. 
GAPDH 
CATK 
COL1 
Figure 25 - Osteoclastic and osteoblastic-related genes 
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4.5.8 Involvement of some osteoclastogenesis-related signaling 
pathways on cellular response  
 
 
 
 
 
 
 
 
 
 
 
 
In the control, TRAP activity decreased in the presence of all tested signaling 
pathways inhibitors, especially in the case of PDTC that sharply abolished TRAP 
activity. The one exception was U0126, which did not affect cellular response at day 21. 
Comparatively, the presence of U0126 seemed to affect the cellular response in cell 
cultures treated with all tested AEDs, except carbamazepine. When supplemented with 
AEDs, the presence of PDTC also abolished TRAP activity to low values. In the 
presence of the tested AEDs, GO6983 elicited a decrease on TRAP activity lower 
(carbamazepine and topiramate) or similar to the one observed in the control. 
Supplementation with SP600125 caused a higher inhibitory effect in the presence of all 
AEDs.  
Figure 26 - TRAP Activity of co-cultures performed in the presence of different AEDs. Cell cultures 
were supplemented with different osteoclastogenic and osteoblastogenic-related signaling pathways, 
namely U0126 (MEK inhibitor), PDTC (NFkB inhibitor), GO6983 (PKC inhibitor) and SP600125 
(JNK inhibitor). * Significantly different from the control.  
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4.5.9 Involvement of some osteoblastogenesis-related signaling 
pathways on cellular response  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the control, ALP activity decreased in the presence of all tested signaling 
pathways inhibitors. Comparatively, the presence of U0126 did not affect cellular 
response in the presence of carbamazepine and lamotrigine, while cultures 
supplemented with topiramate and valproic acid exhibited a higher inhibition. No 
inhibition was also observed in the presence of PDTC in carbamazepine-treated cell 
cultures.  GO6983 significantly affected the cellular response in cell cultures treated 
with the AEDs, except in the case of gabapentin. Supplementation with SP600125 
affected the behavior of cultures maintained in the presence of all tested AEDs, 
although at a lower significance than the one observed in the absence of the drugs. 
Figure 27 - ALP activity of co-cultures performed in the presence of different AEDs. Cell cultures were 
supplemented with different osteoclastogenic and osteoblastogenic-related signaling pathways, namely 
U0126 (MEK inhibitor), PDTC (NFkB inhibitor), GO6983 (PKC inhibitor) and SP600125 (JNK 
inhibitor). * Significantly different from the control. 
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5.1 Discussion  
The precise balance between bone formation and bone resorption is critical for the 
maintenance of bone mass density and systemic mineral homeostasis. These events are 
responsible for the life-long bone remodeling in order to ensure a healthy tissue 
formation and maintenance. Any disturbance of this balance may lead to various bone 
diseases (9, 14). In this work, cultures of human osteoclastic, osteoblastic and co-
cultures of both cells were used as an in vitro model to address the effects of AEDs on 
bone metabolism. 
Antiepileptic drugs were first associated with bone disorders in both adults and 
children in the late 1960s (51). The most severe manifestations of these disorders are 
osteopenia/osteoporosis, osteomalacia and fractures (52).  
There are conflicting reports on effects of AEDs on bone strength and metabolism. 
Furthermore, the effects of AEDs on the osteoclast and osteoblast development are 
scarcely reported in the literature, with only a few published studies about it. In 
addition, these studies are mostly performed in vivo. Thus, without a detailed 
characterization of the in vitro effects of AEDs on bone cells, the knowledge about the 
underlying mechanisms is still unknown. 
* 
PBMC cultures were performed in the presence of the osteoclastogenic 
recombinant growth factors M-CSF and RANKL. A number of studies have shown that 
both, M-CSF and RANKL, are required to induce the expression of genes that typify the 
osteoclast lineage, such as TRAP (an important cytochemical marker of osteoclasts, 
whose concentration in serum is used as a biochemical marker of osteoclast function 
and degree of bone resorption (53)), CTR, VNR (11).  
The different AEDs had the ability to modulate the osteoclastogenic process. 
The majority of the tested AEDs (carbamazepine, gabapentin, lamotrigine and 
topiramate) negatively modulated it, leading to a decrease on osteoclastogenesis. This 
situation was observed by quantification of TRAP activity, number of TRAP+ 
multinucleated cells and calcium phosphate resorbing ability. All obtained results 
showed a dose-dependent decrease on the cellular response. Valproic acid appeared as 
an exception since, at lower doses (10
-7
 M), caused an increase on the process. 
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However, higher concentrations elicited a dose-dependent inhibition on osteoclast 
development. 
Caspase-3 activity results were also in line with these findings, since 
supplementation with carbamazepine, gabapentin, lamotrigine and topiramate elicited a 
dose-dependent increase of caspase-3 activity. However, supplementation with valproic 
acid caused a decrease of caspase-3 activity at 10
-6
M concentration, suggesting that this 
drug may stimulate osteoclastogenesis by increasing cell survival. 
NFkB pathway seemed to be crucial in all tested conditions (control and 
presence of AEDs), which strongly suggests that, in our culture conditions, this can be a 
major osteoclastogenic intracellular mechanism. PKC signaling pathway did not 
contribute to the cellular response in PBMC cultures treated with lamotrigine and 
valproic acid, although in the presence of the remaining AEDs it elicited a decrease on 
TRAP activity slightly higher than the one observed in the control. JNK pathway was 
down regulated by carbamazepine, while supplementation with lamotrigine, topiramate 
and valproic acid exhibited a significantly higher involvement of that pathway on 
osteoclastic response.  
The osteoblastic cells have a fundamental role in  bone  formation  and 
regeneration producing extracellular matrix proteins and regulators of matrix 
mineralization (12). The proliferation/viability of osteoblasts was performed by the 
MTT assay. Cell proliferation is the measurement of the number of cells that are 
dividing in a culture. Cell viability can be defined as the number of healthy cells in a 
sample. Whether the cells are actively dividing or are quiescent is not distinguished 
(54). It was observed that when supplemented with low doses of different AEDs, 
cellular behavior didn’t significantly change. At high doses, all AEDs caused a dose-
dependent non-significantly decrease on cellular proliferation / viability. In line with 
this, supplementation with carbamazepine, lamotrigine, topiramate and valproic acid 
elicited a dose-dependent increase of caspase-3 activity. Supplementation with 
gabapentin caused a small decrease of caspase-3 activity at 10
-6
M concentration, while 
at 10
-4
M it was observed an increase on cell response. 
  Osteoblastic cells were also tested for ALP activity. ALP was the first 
biochemical marker of bone turnover and is still the one most widely used in clinical 
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practice (55). The majority of the tested AEDs (carbamazepine, gabapentin, lamotrigine 
and topiramate) negatively modulated osteoblastogenesis, leading to a dose-dependent 
decrease of ALP activity. Valproic acid appeared as an exception since at lower doses 
caused an increase of ALP Activity. 
Osteoblastic cell cultures were also tested for the involvement of several 
signaling pathways (MEK, NFkB, PKC and JNK). Some significant alterations on the 
contribution of the tested pathways on the response of osteoblastic cells were observed. 
PKC pathway appeared to be crucial in all tested conditions (control and presence of 
AEDs, except for gabapentin), which strongly suggests that, in our culture conditions, 
this one can be one of the major osteoblastogenic intracellular mechanism. NFkB 
signaling pathway did not significantly contribute to the cellular response in osteoblastic 
cell cultures treated with carbamazepine, although in the presence of the remaining 
AEDs it elicited a decrease on ALP activity slightly higher than the one observed in the 
control. MEK signaling pathway did not contribute to the cellular response in 
osteoblastic cell cultures treated with carbamazepine and lamotrigine, while in the 
presence of the remaining AEDs it elicited a decrease on ALP activity slightly higher 
than the one observed in the control. JNK signaling pathway affected the behavior of 
cultures maintained in the presence of all tested AEDs, although at a lower significance 
than the one observed in the absence of the drugs.  
 
Osteoclast-osteoblast communication occurs at the initiation, transition and 
termination phases of bone remodeling. There are at least three modes of 
communication between these cells types. Osteoclasts and osteoblasts can make direct 
contact, form gap junctions or communicate through diffusible paracrine factors (14). In 
co-cultures, TRAP activity was stimulated by valproic acid however, the remaining 
AEDs caused a decrease in osteoclastogenesis. Number of TRAP+ multinucleated cells 
supported these results. The same profile was observed in PBMC cultures, for TRAP 
activity and number of TRAP+ multinucleated cells.  Co-cultures also showed a high 
osteoblastic response at low doses of valproic acid. The remaining AEDs caused a 
decrease in osteoblasts differentiation.  The same results were observed in osteoblastic 
cell cultures, for ALP activity.  
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Caspase-3 activity test was not performed in co-cultures because, since both 
cells were present, it was impossible to know which cell was contributing to the result. 
Co-cultures were also analyzed for the involvement of several signaling 
pathways, either for osteoclastic and osteoblastic parameters. Concerning the 
osteoclastic response, it was observed that, in the control, the tested inhibitors caused a 
decrease in TRAP activity, which indicates that all the signaling pathways influence 
osteoblastic differentiation. The MEK signaling pathway seemed to be closely involved 
in osteoclastogenesis in the presence of all the tested AEDs, except in the presence of 
carbamazepine which appeared not to interfere with. NFkB and JNK signaling 
pathways appeared to be major intracellular mechanisms, being the latter up regulated 
by all the tested AEDs. PKC signaling pathway seemed not to be involved in 
osteoclastogenesis in the presence of carbamazepine, while in the presence of the 
remaining AEDs it elicited a decrease on TRAP activity.  
Regarding the intracellular signaling pathways involving osteoblastic response, 
it was observed that, in the control, the tested inhibitors caused a decrease in ALP 
activity, which indicates that all the signaling pathways influence osteoblastic 
differentiation. Cell cultures treated with carbamazepine and lamotrigine were not 
significantly affected by U0126, which suggests that in these conditions MEK pathway 
may not be important for osteoblastogenesis. Also NFkB seemed not to be important in 
the presence of carbamazepine. Cultures treated with all the tested AEDs, except 
gabapentin, were significantly affected by GO6983, which suggests that in these 
conditions PKC signaling pathway may be important for osteoblastogenesis. JNK 
signaling pathway appeared to be important for osteoblastogenesis. This pathway 
affected the behavior of cultures maintained in the presence of all tested AEDs, 
although at a lower significance than the one observed in the absence of the drugs.  
Taken together, AEDs seemed to cause a direct effect on human osteoclastic and 
osteoblastic differentiation. Interestingly, some of the tested molecules increased while 
others inhibited the processes in a dose-dependent profile. Furthermore, since in the co-
culture, the AEDs influence in both cellular activities was somehow different, this 
suggests that AEDs may also modulate the reciprocal communications established 
between osteoclasts and osteoblasts.  
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It is important to analyze the therapeutic level of the tested AEDs, so that, we 
can compare with the tested concentrations and draw more conclusions. These values 
are presented in Table 5.     
Table 5 - Therapeutic level for the AEDs 
AED 
Tested 
concentrations 
(mol/dm
3
) 
Tested 
concentrations 
(mg/L) 
Therapeutic 
level (mg/L) 
Ref 
CARBAMAZEPINE 10
-8
 -  10
-4
 0,00236 – 23,6 4 – 12 (56) 
GABAPENTIN 10
-8
 -  10
-4
 0,00171 – 17,1 2 – 20 (57) 
LAMOTRIGINE 10
-8
 -  10
-4
 0,00256 – 25,6 3 – 14 (57) 
TOPIRAMATE 10
-8
 -  10
-4
 0,00336 – 33,6 5 – 20 (57) 
VALPROIC ACID 10
-8
 -  10
-4
 0,00144 – 14,4 50 – 100 (56) 
 
 
 
 
Looking at Table 5, it is possible to understand that the therapeutic levels of all 
the tested AEDs, except valproic acid, are within the range of tested concentrations. The 
therapeutic levels represent the AED serum range and it is important to note that bone 
concentrations might be lower. However, we also tested the cells for concentrations 
lower than the therapeutic level, which may reflect bone concentrations of these drugs. 
Taken together, the present results revealed that the tested AEDs interfere with 
bone cells development, at doses that are below the plasma levels found in patients 
undergoing AEDs therapeutics.  
 
Therapeutic level within the range of tested concentrations  
Part of the therapeutic level within the range of tested concentrations  
Therapeutic level out of the range of tested concentrations  
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AED-induced disturbances of bone integrity are mainly influenced by the type, 
dosage and duration of the AED therapy. A dose-dependent increase in the risk of 
fractures was particularly observed during therapy with carbamazepine (33). Several 
studies have concluded that AEDs such as carbamazepine have long been known to 
have an adverse effect on bone health (58, 59) which maybe can be justified by the 
decrease on osteoclastogenesis and osteoblastogenesis, observed in our study. In 
addition to the negatively modulation of these processes, Lee R. H. , et al  (60) also 
summarized that carbamazepine led to increased metabolism of 25-hydroxyvitamin D to 
inactive metabolites, which resulted in metabolic bone disease. Thus, AEDs seem not 
only to affect bone cells, but also other molecules involved in bone remodeling process. 
In 2008, this fact was also documented by Bortolini L., et al (61). They suggested that 
the AEDs may interfere in the mineral bone metabolism by different mechanisms 
including direct effects over the bone cells, changes in the metabolism and/or in the 
action of the vitamin D in target organs, hypocalcemia and actions over the sexual 
steroids. Besides, Feldkamp J., et al (62) suggested that AEDs are recognized to have 
direct effects on bone cells, inhibiting the bone formation process, which supports our 
results. In their experimental studies, Feldkamp J., et al (62)also concluded that 
carbamazepine revealed no proliferation stimulating properties, which supports our 
results obtained by MTT assay: for concentrations lower than 10
-5
 M, carbamazepine 
did not significantly affect the cellular proliferation. In a study performed by Valimaki 
M., et al (63) they concluded that antiepileptic treatment with carbamazepine 
accelerates skeletal turnover. They also indicated that AEDs may directly affect the 
function of bone cells, in in vitro studies, which supports our results. Despite several 
studies have concluded that carbamazepine negatively affect bone metabolism, Sheth R. 
(18) summarized that carbamazepine has not been shown to have a predictable effect on 
bone mineral density.    
According to previous studies (38, 43, 59) gabapentin therapy may cause bone 
loss, which can be justified by the results obtained in our study: as osteoclastogenesis is 
affected, bone remodeling does not occur properly. Gabapentin is also not free from this 
important adverse effect (59). However, only a few studies on this drug were performed.   
Data regarding lamotrigine effects on bone is mixed (64). Other studies 
indicated that lamotrigine monotherapy may not have significant impact on bone 
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metabolism, which does not support our results (24, 65). However Sheth R. (18) and 
Verrotti A. (59) indicated that lamotrigine was associated with reduced bone formation, 
which supports our results. Osteoblasts are bone-forming cells and its function was 
decreased in the presence of this drug, as it is possible to see in Figure 9.  
Topiramate effects on bone were the subject of a limited amount of studies (64). 
Topiramate also does not seem to be associated with alterations of bone metabolism 
(58, 59), however, a recent study demonstrated that long-term topiramate treatment 
could have adverse effect on bone, increasing bone turnover (39), that supports our 
results.    
Concerning the effects of valproic acid on bone metabolism, our results are 
compatible with previous publications (28, 59, 66-69), and disagree with some others 
(35, 70, 71). Zare M., et al concluded that their findings indicate that bone mineral 
metabolism may not be affect by valproic acid. They admitted that real causes of 
discrepancies among different studies are not clear, but a long list of different factors 
could be suspected. Age, duration of treatment, type of concurrent drugs used, lifestyle, 
and socioeconomic and geographic conditions are some of the factors that can influence 
valproic acid’s adverse bone effects (70). Either a recent study performed by 
Triantafyllou N., et al (35) showed no correlation between valproic acid monotherapy 
and bone mineral density measurements. However, Verrotti A., et al (66) have reported 
that markers of bone formation such as ALP have been significantly increased with this 
drug, which is compatible with the results obtained for ALP activity. An in vitro study 
performed by Hatakeyama Y., et al (67) cell morphology alterations were examined 
observing F-actin-stained cytoskeleton content at various concentrations of valproic 
acid. That data suggests that valproic acid was able to maintain normal cell shape, 
which supports our results obtained for osteoblastic cell cultures assessed by CSLM. No 
changes in cell morphology were observed. Moreover, they also performed a cell 
proliferation test concluding that the effect of valproic acid on cell proliferation is 
dependent on the maturation level of the cells, namely that immature cells have 
resistance to high concentrations of valproic acid. Another study performed by Sato Y., 
et al (72) suggested that valproic acid directly acts over the osteoblasts, which also 
corroborates our results. Also Samaniego E. et al (30) agreed that AEDs may affect 
bone density by possible altering osteoblastic function and Valsamis H., et al (69) 
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refered that valproic acid may cause an imbalance between bone formation and 
resorption, contributing to bone loss. A study referenced by Tsiropoulos I., et al (73) 
concluded that this drug enhance osteoblast viability and differentiation in low 
concentrations. Results obtained for ALP activity were in conform with this conclusion, 
because valproic acid at lower doses caused an increase of ALP activity.   Sheth R. (18) 
suggested that bone turnover increased with valproic acid, and we can justified this with 
the increased observed in our results for ALP activity. Considering these results, it is 
possible to think that, if valproic acid increase ALP activity, it means that, probably this 
drug might stimulate the osteoblastogenesis process. However, we should consider that 
excess remodeling reduces bone mass, while suppressed bone remodeling increases it. 
Bone strength is determined not only by mass but by bone quality. Suppressed bone 
remodeling likely reduces bone quality due to accumulation of micro fractures and 
reduced restructuring of bone architecture (14). So, even though we have obtained an 
increase on ALP activity in the presence of valproic acid, it is important to keep in mind 
that, for the same concentration that caused this increase, we observed a decreased of 
TRAP activity. Therefore, a proper balance between bone formation and bone 
resorption may not exist, which makes this increase an adverse effect. According Sheth 
R., et al (74) the pathogenesis of valproic acid-associated reduction in bone mineral 
density remains undefined. This drug does not interfere with the absorption of either 
calcium or phosphorus. Thereafter, the most likely reason for the negative impact of 
valproic acid on bone metabolism seems to be the direct effect on bone cells, as our 
study proves. They also suggested that valproic acid negatively affect bone metabolism 
by stimulating osteoclast activity and causing imbalance between bone formation and 
resorption.  
Considering the results obtained with co-cultures results, some differences were 
found comparatively to the results obtained for PBMC and osteoblastic cell cultures, 
suggesting that AEDs might also indirectly modulate the osteoclastogenic and 
osteoblastogenic properties of osteoblasts and osteoclasts, respectively. These 
differences can be justified by the osteoclast-osteoblast communication, as described by 
Matsuo K., et al (14) “Osteoclasts and cells in the osteoblast lineage can communicate 
through cell-cell contact to achieve “coupling” of bone resorption to formation. (…) 
Initiation of osteoclastogenesis largely depends on interaction between osteoclasts 
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precursors and cells in the osteoblast lineage.” In our study we cannot say how they 
influence each other, but we observed that it happens. 
Regarding the intracellular mechanisms involved in osteoclast and osteoblast 
response to AEDs, no studies were found with in vitro assays with signaling pathways. 
Thus, our study is the first one that goes into this issue.  
Fitzpatrick L. (41) resumed some information about in vitro studies of AEDs. 
Although the studies summarized were just about phenytoin, a drug that was not used in 
our study, some conclusions are important. Not only with the drugs that we study, but 
also with phenytoin the mechanism(s) of drug-induced bone loss remains unexplained 
and appears to be multifactorial. The in vitro studies performed with this drug also 
reported that at micro molar concentrations phenytoin interfere with proliferation  and 
differentiation of bone cells and may act on the resorption side of the bone remodeling 
process. This drug seemed to inhibit bone resorption at high doses and may have a more 
direct action on bone formation. Fitzpatrick L. (41) suggested that the discrepancy in 
findings of in vitro studies may be due to the higher doses of drug that are required to 
inhibit bone formation, whereas lower doses may inhibit bone resorption. Besides, it 
was suggested a toxic effect on bone formation at doses that are given to patients. 
Inhibition of osteoblast-like cells could impair bone formation, leading to bone loss. 
We should keep in mind that unraveling the mechanisms beneath these 
observations might help to explain the adverse effects on bone tissue described for this 
drug class.  
According Pack A., et al (52) several theories have been proposed to explain the 
link between AEDs and bone disease. Possible mechanisms include: a) hepatic 
induction of the cytochrome P450 leading to increased catabolism of vitamin D; b) a 
direct effect on bone cells, including an impairment of absorption of calcium and 
inhibition of response to PTH; c) hyperparathyroidism and d) calcitonin deficiency. In 
general, literature affirms that cytochrome P450 enzyme-inducing AEDs (such as 
carbamazepine) are most commonly associated with a negative impact on bone instead 
of the new-generation AEDs (such as gabapentin, lamotrigine and topiramate). 
However, no standard were found.   
Taken together, the published studies were performed in different experimental 
models, of different origins and mainly in vivo models, which can help to explain the 
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contradictions found among the data obtained. Besides, Beerhorst K., et al (68) also 
refers that there are several AEDs on the market, but long-term follow-up of possible 
side effects on bone is still lacking. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 – Conclusion and future directions 
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6.1 Conclusion  
Several risk factors have been suggested to contribute to bone disease in patients 
with epilepsy: polytherapy, age above 50 years, use of AEDs for more than 2 years and 
use of enzyme-inducing AEDs (37). Multiple therapies for bone disease are available 
including high-dose vitamin D supplementation (improved bone mineral metabolism), 
calcium supplementation (slowed the rate of bone loss), bisphosphonates (potent 
inhibitors of bone resorption), hormone replacement therapy (efficient in stopping bone 
loss but with side effects), selective estrogen receptor modulators (increased bone mass 
and reduces the risk of fractures), calcitonin (reduced the rate of fractures) and vitamin 
K supplementation (retardation of bone loss). However, international guidelines 
concerning screening for osteoporosis in people with epilepsy have not been established 
due to the lack of convincing studies. Triantafyllou N., et al (35) performed an in vivo 
study to evaluate the effect of long-term valproate monotherapy on BMD concluding 
that there are no correlation between duration or dosage of valproate monotherapy with 
BMD measurements. Moreover, scores were similar between patients and age and sex-
matched controls. Thus, studies of the effect of AEDs on bone metabolism have yielded 
contradictory results.  
A recent study performed by Beerhorst K., et al (37) strongly suggest that long-term 
AED use is associated with an extreme high prevalence of osteoporosis and osteopenia. 
The prevalence rate of low BMD of 80% in this study underscores the need for more 
bone health awareness in patients with epilepsy. Taking into account our and other 
studies that corroborate this relation between AEDs and bone metabolism, maybe the 
early screening, careful guidance of lifestyle factors, supplementation of vitamin D and 
calcium, and a critical or even restrictive attitude towards long-term treatment with a 
high drug load of AEDs should be justified.  
The adverse metabolic effects of AEDs are probably currently underestimated, and 
thus represent an area of legitimate concern. 
A long way still has to be traversed. More in vitro studies must be performed, to 
help in the understanding of direct effect of AEDs on bone cells.  
More studies are needed and the newer AEDs may be less likely to have a negative 
impact on bone, although this remains to be studied too. Physicians and epileptologists 
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should consider the endocrine effects of AEDs and concerns about epilepsy itself. It is 
important to monitor blood parameters of metabolism, like bone markers (51). It is 
imperative to act on the improvement of the quality of life of patients and their health 
status in general. Neurologists often do not think about bone health, although there may 
be good reason to (75).  
The aims of this study were fulfilled. The effects of AEDs in human bone cells 
were studied, firstly, by the focus on the influence of different concentrations of five 
different AEDs in the osteoclastogenic and osteoblastogenic process. AEDs differently 
modulated the osteoclastic and the osteoblastic behavior of PBMC, osteoblasts and co-
cultures of both cell types. With the purpose of had some insights on the mechanisms of 
action of AEDs on bone cells, the influence of several signaling pathways on cellular 
response was performed.   
In summary, this work provides new insights on the in vitro effects of AEDs on 
human bone cells and opens the doors towards a better understanding about this up till 
now poorly clarified issue. 
 
6.2 Future directions  
In the future, we should try to introduce other molecules, for example vitamin K2. 
In the review written by Plaza S., et al (76) it stated that vitamin K2 exerts a powerful 
influence on bone building and, thus, may be regarded as a potential partner in AEDs 
therapeutics, in order to counteract deleterious effects in bone tissue.  
Another idea is to perform, at the same time, a clinical and an experimental study, 
analyzing patients and their cells. The same strategy was used by Feldkamp J., et al 
(62).  
Furthermore, the duration of the study should be expanded, so that we can evaluate 
long-term effects. It is important to keep in mind that, during an in vitro study, it’s 
possible to follow-up in real time the direct effects of AEDs on bone cells. These micro 
effects probably may take years to reveal symptoms, to be evidenced by our body. 
Regarding the referenced in vivo studies that affirmed that there is no relationship 
between AEDs and bone metabolism, this could be the proper reason: If they performed 
a 2 years follow-up, AEDs already started to change bone cells however, these changes 
Characterization of the effects of antiepileptic drugs on bone metabolism: In vitro studies with human 
osteoblastic and osteoclastic cells 
71 
 
are not visible through bone mineral density yet. Also, Samaniego E., et al (30) also 
suggested that in mild cases, patients are asymptomatic and have normal bone mass.  
It will also be interesting to try to test bone cells with combined AEDs. Tsiropoulos 
I., et al (73) declared that polytherapy was associated with a higher risk than 
monotherapy.   
In order to have a more accurate perspective of the effects of AEDs on human bone 
metabolism, it is imperative to evaluate the way human bone cells behave in the 
presence of those molecules. There is no data regarding this issue so far. On the other 
hand, it is important to note that this study represents only the first step towards a 
physiological understanding of how AEDs may affect bone tissue. A correlation to the 
clinical situation cannot be directly predicted, due to the complex in vivo environment.
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